Company intelligence / Profile preview

Tanabe Pharma America

Jersey City, New Jersey, United States

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Mitsubishi Tanabe Pharma America (MTPA) is the U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation, a top-tier Japanese pharmaceutical company. MTPA focuses on commercializing innovative therapies for patients with unmet medical needs, particularly in the fields of neurology and rare diseases. The company is best known for the U.S. launch of Radicava (edaravone), the first FDA-approved treatment for Amyotrophic Lateral Sclerosis (ALS) in over 20 years. MTPA continues to expand its portfolio through internal development and strategic partnerships, aiming to provide life-changing treatments for complex conditions.

Therapeutic areas: Neurology
Modalities: Small moleculeMonoclonal antibodyBiologic
Industry: Biotech

Partnerships

NeuroDermAquestive Therapeutics

Beyond the preview

Go deeper on Tanabe Pharma America.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tanabe Pharma America.

Explore the full profile